Orientation Averaging of Optical Chirality Near Nanoparticles and Aggregates

Artificial nanostructures enable fine control of electromagnetic fields at the nanoscale, a possibility that has recently been extended to the interaction between polarised light and chiral matter. The theoretical description of such interactions, and its application to the design of optimised structures for chiroptical spectroscopies, brings new challenges to the common set of tools used in nano-optics. In particular, chiroptical effects often depend crucially on the relative orientation of the scatterer and the incident light, but many experiments are performed with randomly-oriented scatterers, dispersed in a solution. We derive new expressions for the orientation-averaged local degree of optical chirality of the electromagnetic field in the presence of a nanoparticle aggregate. This is achieved using the superposition T -matrix framework, ideally suited for the derivation of efficient orientation-averaging formulas in light scattering problems. Our results are applied to a few model examples, and illustrate several non-intuitive aspects in the distribution of orientation-averaged degree of chirality around nanostructures. The results will be of significant interest for the study of nanoparticle assemblies designed to enhance chiroptical spectroscopies, and where the numerically-efficient computation of the averaged degree of optical chirality enables a more comprehensive exploration of the many possible nanostructures

The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia

Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B‐cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories ≥75 and <75 years treated in the relapsed, refractory non‐trial setting. We demonstrate that venetoclax has equivalent efficacy and safety in relapsed/refractory CLL patients who are elderly, the majority of whom are previous ibrutinib‐exposed and therefore may otherwise have few clear therapeutic options.<br